Literature DB >> 26232370

Can the Lung Cancer Pie Be Divided into Angiogenic Slices?

Tina Cascone1, John V Heymach2.   

Abstract

There are no validated markers for predicting benefit from angiogenesis inhibitors or classifying tumors with distinct angiogenic phenotypes. In patients with non-small cell lung cancer treated with bevacizumab and erlotinib, Franzini and colleagues find that angiogenesis- and hypoxia-associated gene expression signatures predict tumor response and/or clinical outcome, and may define distinct angiogenic patterns. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26232370      PMCID： PMC4668212          DOI： 10.1158/1078-0432.CCR-15-1180

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Biomarkers in cancer immunotherapy.

Authors:  Ton N Schumacher; Can Kesmir; Marit M van Buuren
Journal:  Cancer Cell       Date:  2015-01-12       Impact factor: 31.743

Review 2.  The role of hypoxia-induced factors in tumor progression.

Authors:  Peter Vaupel
Journal:  Oncologist       Date:  2004

3.  Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).

Authors:  Anca Franzini; Florent Baty; Ina I Macovei; Oliver Dürr; Cornelia Droege; Daniel Betticher; Bogdan D Grigoriu; Dirk Klingbiel; Francesco Zappa; Martin H Brutsche
Journal:  Clin Cancer Res       Date:  2015-04-28       Impact factor: 12.531

4.  Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

Authors:  Roy S Herbst; Rafat Ansari; Frederique Bustin; Patrick Flynn; Lowell Hart; Gregory A Otterson; Gordana Vlahovic; Chang-Heok Soh; Paula O'Connor; John Hainsworth
Journal:  Lancet       Date:  2011-05-28       Impact factor: 79.321

5.  Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

Authors:  Tina Cascone; Matthew H Herynk; Li Xu; Zhiqiang Du; Humam Kadara; Monique B Nilsson; Carol J Oborn; Yun-Yong Park; Baruch Erez; Jörg J Jacoby; Ju-Seog Lee; Heather Y Lin; Fortunato Ciardiello; Roy S Herbst; Robert R Langley; John V Heymach
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

6.  Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Authors:  Hai T Tran; Yuan Liu; Amado J Zurita; Ying Lin; Katherine L Baker-Neblett; Anne-Marie Martin; Robert A Figlin; Thomas E Hutson; Cora N Sternberg; Rafael G Amado; Lini N Pandite; John V Heymach
Journal:  Lancet Oncol       Date:  2012-07-02       Impact factor: 41.316

7.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

8.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

9.  Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).

Authors:  Francesco Zappa; Cornelia Droege; Daniel Betticher; Roger von Moos; Lukas Bubendorf; Adrian Ochsenbein; Oliver Gautschi; Elisabeth Oppliger Leibundgut; Patrizia Froesch; Rolf Stahel; Thomas Hess; Daniel Rauch; Petra Schmid; Michael Mayer; Susanne Crowe; Peter Brauchli; Karin Ribi; Miklos Pless
Journal:  Lung Cancer       Date:  2012-09-23       Impact factor: 5.705

10.  Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.

Authors:  George R Blumenschein; Pierre Saintigny; Suyu Liu; Edward S Kim; Anne S Tsao; Roy S Herbst; Christine Alden; J Jack Lee; Ximing Tang; David J Stewart; Merrill S Kies; Frank V Fossella; Hai T Tran; L Mao; Marshall E Hicks; Jeremy Erasmus; Sanjay Gupta; Luc Girard; Michael Peyton; Lixia Diao; Jing Wang; Suzanne E Davis; John D Minna; Ignacio Wistuba; Waun K Hong; John V Heymach; Scott M Lippman
Journal:  Clin Cancer Res       Date:  2013-10-28       Impact factor: 12.531
View more
  1 in total

1.  VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop.

Authors:  Asma Boudria; Cherine Abou Faycal; Tao Jia; Stephanie Gout; Michelle Keramidas; Chloé Didier; Nicolas Lemaître; Sandra Manet; Jean-Luc Coll; Anne-Claire Toffart; Denis Moro-Sibilot; Corinne Albiges-Rizo; Véronique Josserand; Eva Faurobert; Christian Brambilla; Elisabeth Brambilla; Sylvie Gazzeri; Beatrice Eymin
Journal:  Oncogene       Date:  2018-09-07       Impact factor: 9.867
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.